carbimazole

Phase 3Small molecule

NNewcastle-upon-Tyne Hospitals NHS Trust

carbimazole is one of 5 small molecule programs targeting Thyrotoxicosis. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

ThyrotoxicosisActive, not recruiting

ThyrotoxicosisPhase 3

Active, not recruiting

Competition

Competitive Landscape

4 competitors in Thyrotoxicosis

#DrugCompanyPhaseTrials

Thyroxine

WWashington University School of Medicine

Phase 3

1 2

Propylthiouracil

AAultman Health Foundation

Phase 3

1 3

carbimazole

NNewcastle-upon-Tyne Hospitals NHS Trust

Phase 3

1 4

Potassium Iodide

DDawnrays Pharmaceutical (Holdings) Limited

Preclinical

—5

Thiamine

UUniversiti Kebangsaan Malaysia Medical Centre

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Thyrotoxicosis1 trial

Antithyroid Drug Treatment of Thyrotoxicosis in Young People

Completed·NNewcastle-upon-Tyne Hospitals NHS Trust·Phase 3·NCT01436994·81 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for carbimazole. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — carbimazole compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for carbimazole. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Newcastle-upon-Tyne Hospitals NHS Trust company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: NNewcastle-upon-Tyne Hospitals NHS Trust

carbimazole

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Thyrotoxicosis1 trial

References

Drug Info

Quick Facts

Related News